INTRODUCTION: Several new agents are being tested in clinical trials for patients with non-small cell lung cancer (NSCLC). A survey of ongoing clinical trials in NSCLC in the ClinicalTrials.gov website would help identify areas that require further attention in the future. METHODS: We conducted a survey of ongoing clinical trials on NSCLC registered in the ClinicalTrials.gov website. The advanced search option was applied using the terms "non small cell lung cancer," "open studies," "interventional," and "adults 18 years or older." RESULTS: Of the 493 eligible trials, 77 (15.6%) were phase III, 92 (18.7%) were phase I, and 240 (48.7%) were phase II trials. Universities were listed as the primary sponsor for 224 (45.4%) trials and pharmaceutical industry for 166 (33.7%) trials. Majority of the trials were multicenter studies (56.8%) and were being conducted exclusively within the United States (51.3%). A large proportion of phase II and III clinical trials (77.2%) were focused on patients with advanced-stage disease. The most frequently used end points were progression-free survival (27.1%) followed by tumor response rate (22.9%) and overall survival (16.6%). Although biomarker analysis was included in 185 (37.5%) trials, only 39 (7.9%) trials used biomarkers for patient selection. CONCLUSIONS: Progression-free survival is the end point most commonly used to assess the effectiveness of experimental regimens, and biomarker-based patient selection is rarely used in ongoing clinical trials for NSCLC.
INTRODUCTION: Several new agents are being tested in clinical trials for patients with non-small cell lung cancer (NSCLC). A survey of ongoing clinical trials in NSCLC in the ClinicalTrials.gov website would help identify areas that require further attention in the future. METHODS: We conducted a survey of ongoing clinical trials on NSCLC registered in the ClinicalTrials.gov website. The advanced search option was applied using the terms "non small cell lung cancer," "open studies," "interventional," and "adults 18 years or older." RESULTS: Of the 493 eligible trials, 77 (15.6%) were phase III, 92 (18.7%) were phase I, and 240 (48.7%) were phase II trials. Universities were listed as the primary sponsor for 224 (45.4%) trials and pharmaceutical industry for 166 (33.7%) trials. Majority of the trials were multicenter studies (56.8%) and were being conducted exclusively within the United States (51.3%). A large proportion of phase II and III clinical trials (77.2%) were focused on patients with advanced-stage disease. The most frequently used end points were progression-free survival (27.1%) followed by tumor response rate (22.9%) and overall survival (16.6%). Although biomarker analysis was included in 185 (37.5%) trials, only 39 (7.9%) trials used biomarkers for patient selection. CONCLUSIONS: Progression-free survival is the end point most commonly used to assess the effectiveness of experimental regimens, and biomarker-based patient selection is rarely used in ongoing clinical trials for NSCLC.
Authors: Patrick T Hennessey; Tiffany Sanford; Ashish Choudhary; Wojciech W Mydlarz; David Brown; Alex Tamas Adai; Michael F Ochs; Steven A Ahrendt; Elizabeth Mambo; Joseph A Califano Journal: PLoS One Date: 2012-02-28 Impact factor: 3.240
Authors: Jianda Yuan; Priti S Hegde; Raphael Clynes; Periklis G Foukas; Alexandre Harari; Thomas O Kleen; Pia Kvistborg; Cristina Maccalli; Holden T Maecker; David B Page; Harlan Robins; Wenru Song; Edward C Stack; Ena Wang; Theresa L Whiteside; Yingdong Zhao; Heinz Zwierzina; Lisa H Butterfield; Bernard A Fox Journal: J Immunother Cancer Date: 2016-01-19 Impact factor: 13.751
Authors: Arno Amann; Marit Zwierzina; Gabriele Gamerith; Mario Bitsche; Julia M Huber; Georg F Vogel; Michael Blumer; Stefan Koeck; Elisabeth J Pechriggl; Jens M Kelm; Wolfgang Hilbe; Heinz Zwierzina Journal: PLoS One Date: 2014-03-24 Impact factor: 3.240
Authors: Frances E Lennon; Tamara Mirzapoiazova; Bolot Mambetsariev; Valeriy A Poroyko; Ravi Salgia; Jonathan Moss; Patrick A Singleton Journal: PLoS One Date: 2014-03-24 Impact factor: 3.240